latest update:
[TrialBase DB]

trial summary · NCT06902012

Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma

A Prospective, Single - Arm Clinical Study on the Safety and Efficacy of Early Second Infusion of CD19 CAR - T Based on ctDNA Monitoring in the Treatment of Relapsed/Refractory Large B - Cell Lymphoma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Relapsed/Refractory Diffuse Large B-cell Lymphoma, sponsored by Zhujiang Hospital. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06902012phase PHASE1/PHASE2enrollment 15start 2027-02

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this clinical trial is to evaluate the efficacy and safety of early secondary infusion of CD19 CAR T-cell therapy in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), guided by ctDNA monitoring. The main questions it aims to answer are: 1. Efficacy: Does early secondary CAR-T infusion improve the 3-month complete remission (CR) rate and long-term survival outcomes (e.g., 1-year PFS, OS)? 2. Safety: What are the adverse events associated with secondary CAR-T infusion, such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), and infections? This is a single-arm, single-center, prospective study. All participants will receive: * Leukapheresis to collect T cells for CAR-T manufacturing. * Preconditioning chemotherapy (fludarabine and cyclophosphamide) to prepare the body for CAR-T infusion. * Two CD19 CAR-T infusions: The first infusion (2×10⁶ cells/kg) followed by a second infusion (same dose) if ctDNA remains positive when PET/CT shows CR or PET/CT shows PR within 60 days post-first infusion. Participants will undergo: * Frequent hospital monitoring for ≥14 days post-infusion to manage potential toxicities. * Regular follow-ups (e.g., blood tests, ctDNA analysis, PET/CT scans) at scheduled intervals up to 12 months. * Continuous safety assessments, including CRS grading, neurological evaluations, and infection monitoring.

Source record: https://clinicaltrials.gov/study/NCT06902012

Facts

registry idNCT06902012
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionRelapsed/Refractory Diffuse Large B-cell Lymphoma
sponsorZhujiang Hospital
sponsor classOTHER
enrollment15
start date2027-02
primary completion2028-02
completion2028-08
results postednot reported

Conditions

  • Relapsed/Refractory Diffuse Large B-cell Lymphoma

Interventions

  • Infusion of Axicabtagene Ciloleucel

Countries

  • China

Intervention types: DRUG

Work with this record